Article Text

PDF
Finasteride and benign prostatic hyperplasia
  • Relevant BNF sections: 6.4.2, 7.4.1

Abstract

Finasteride (Proscar - MSD), a type II 5α-reductase inhibitor, was introduced in 1992 for the medical treatment of men with benign prostatic hyperplasia. The manufacturer claims that finasteride can "halt the progress of the disease and reverse the disease process" and that "one year of therapy with finasteride reversed more than 15 years' growth in prostate volume". We examine the clinical effectiveness of finasteride and assess these claims.

Statistics from Altmetric.com

  • Relevant BNF sections: 6.4.2, 7.4.1

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.